Sanofi and CRH Shares Plunge Despite Record Results as Markets Demand More

The Quick Take

• Sanofi shares fell 9.33% despite raising full-year 2026 guidance following a strong second quarter driven by Dupixent record sales
• CRH stock declined 7.18% despite posting record profits as investors focused on cash flow concerns rather than earnings growth
• Dupixent continued its blockbuster trajectory but failed to offset investor concerns about Sanofi's non-Dupixent portfolio concentration risk
• CRH trades approximately 25% below its January 2026 year-high despite the record quarterly profit announcement

The European equity markets delivered a counterintuitive lesson Thursday: strong results are no longer sufficient. Sanofi raised its full-year 2026 guidance after an exceptional Q2 driven by record Dupixent revenue, yet shares fell 9.33%. Simultaneously, CRH posted record quarterly profits in its building materials business and watched its stock drop 7.18%. Both cases reflect elevated market expectations entering earnings season — investors had already priced in strong results, and the absence of upside surprise relative to those elevated expectations triggered position unwinding.

Sanofi's selloff despite guidance upgrades highlights a structural concern that markets have been pricing for several quarters: excessive dependence on Dupixent, the IL-4/IL-13 inhibitor, as the single growth engine. If Dupixent faces eventual biosimilar competition or label restrictions, Sanofi's portfolio lacks immediate replacement candidates at comparable revenue scale. CRH's cashflow-focused investor base is reacting to a different signal — construction activity may have peaked in key US and European markets, raising questions about whether record profits can be sustained through 2027 as building cycles turn.

Watch Sanofi's pipeline readout on its late-stage immuno-oncology assets as the next potential catalyst to broaden the growth narrative beyond Dupixent. For CRH, North American residential construction starts and infrastructure contract awards are the forward signals. The macro variable for both is ECB and Fed rate policy — sustained elevated rates constrain construction financing (CRH headwind) while healthcare reimbursement environments are tightening (Sanofi margin risk). Both stocks sitting near cycle lows despite record results suggests the market believes near-term peak has been reached.

Synthesized from 2 sources.